UFP Packaging Announces Nail-Gun-Free Crate Line for Safer Assembly Accessibility StatementSkip Navigation GRAND RAPIDS, Mich., March 24, 2026 /PRNewswire/ -- UFP Packagingdebuted Slot-Lock and Clamp-Lock 100, two new industrial crate systems engineered for nail-gun-free assembly. The additions expand its pneumatic-free product portfolio alongside U-Loc 200, introduced in 2025. The new systems improve workplace safety and efficiency by eliminating the need for nail and staple guns, providing safer alternati ...

Group 1 - The service provided by Crude Value Insights focuses on oil and natural gas investments, emphasizing cash flow and the companies that generate it, which leads to value and growth prospects with real potential [1] - Subscribers have access to a model account with over 50 stocks, in-depth cash flow analyses of exploration and production (E&P) firms, and live chat discussions about the sector [1] Group 2 - A two-week free trial is available for new subscribers, offering an opportunity to explore the oil and gas investment service [2]

NEWBURYPORT, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today announced that President Mitchell Rock and Chief Financial Officer Ron Lataille will participate in a virtual fireside chat at the upcoming KeyBanc Capital Markets Virtual Healthcare Forum on March 18, 2026, beginning at approximately 10:30 AM ET. About UFP Technologies, Inc.UFP Technologie ...

Core Insights - UFP Industries, Inc. (UFPI) is experiencing growth driven by its Deckorators brand and Surestone technology, alongside a successful cost-containment program that saved $35 million in SG&A expenses [1][6][10] Growth Factors - The Deckorators brand has shown exceptional growth, with sales of Surestone mineral-based decking increasing by 44% and wood-plastic composite sales rising by 35% in 2025 [5][6] - The company has operationalized new capacity at its Selma and Buffalo facilities to support an aggressive goal of doubling its composite decking market share [7] - UFP Industries is pursuing acquisitions to complement organic growth, having completed two acquisitions in 2025 with approximately $24 million in historical sales [8][9] - The company maintains a strong balance sheet with $2.2 billion in liquidity, supporting a capital investment plan of $300 million to $325 million for 2026 [11] Challenges - UFP Industries faces headwinds from weak residential construction, which is impacting its Site-Built segment due to affordability challenges and elevated interest rates [12] - The company reported a gross margin contraction of 160 basis points to 16.8% in 2025, with adjusted EBITDA declining by 17.4% year over year [13] - Increased competitive pricing and softer demand in several end markets are creating pressure on sales volumes and margins [13]

UFP Technologies FY Conference Summary Company Overview - **Company Name**: UFP Technologies (NasdaqCM: UFPT) - **Headquarters**: Newburyport, Massachusetts - **Revenue**: Approximately $600 million - **Employees**: Over 5,000 across 21 manufacturing sites and 6 innovation centers - **Focus**: Contract development and manufacturing organization specializing in single-use and single-patient medical devices [2][3] Core Business Insights - UFP Technologies combines design engineering, materials expertise, and precision manufacturing to assist customers in product development and manufacturing [2] - The company has exclusive or semi-exclusive access to various innovative materials, enhancing its competitive edge [3] - The business model has evolved to include product development as a significant revenue stream, previously given away for manufacturing contracts [5] Product Segments - **Robotic Drapes**: Constitutes about 28-29% of the business; significant growth after acquiring a drape manufacturer in the Dominican Republic [6][12] - **Revascularization Devices**: Developed for stroke patients, showcasing the company's capability in sophisticated medical devices [8] - **Safe Patient Handling Products**: Acquired AJR in 2024, which has become a rapidly growing segment [11][12] Market Dynamics - The overall MedTech market is growing at 6%, while outsourced contract development and manufacturing organizations (CDMO) are growing at approximately 10% [12] - UFP Technologies' market segments include 55% devices, 17% sterile packaging, and 28-29% robotic surgery [12] Growth Strategy - The growth strategy is two-pronged: internal growth through marketing to core markets and strategic acquisitions [14][15] - The company aims to double its revenue every five years, having tripled in the last four years [21] - Financial targets include revenue growth of 12%-18%, gross margins of 28%-31%, and adjusted operating margins of 17%-20% [27] Recent Developments - A significant contract extension with a major customer, enhancing volume and duration, which is crucial for capacity planning and investment in new facilities [36] - The company is expanding its footprint in low-cost countries, including Costa Rica and the Dominican Republic, to remain competitive [18][22] Key Challenges and Risks - A recent issue with onboarding employees from an acquisition impacted gross margins, but the situation is largely resolved [27][28] - The company has faced misinformation regarding customer relationships, which has been addressed with contract extensions [29] Future Outlook - UFP Technologies is positioned for growth due to strong customer relationships, a proven management team, and a focus on infection prevention and patient outcomes [24][25] - The company is exploring opportunities in the APAC region, responding to customer demands for geographical expansion [22] Conclusion - UFP Technologies is well-positioned for future growth with a solid strategy, strong market presence, and a focus on innovation and customer needs. The company is optimistic about its trajectory over the next 5-10 years, driven by a committed leadership team and strategic investments [67][68]

Company Overview - UFP Technologies, Inc. designs and manufactures solutions for medical devices, sterile packaging, and engineered custom products in the United States, positioned as a high-quality growth investment in engineered materials and medical device manufacturing [2] - The company serves as a custom development and manufacturing organization (CDMO) for high-growth medical segments, including single-use devices, sterile packaging, and robotic surgery, which is expanding at a mid-teens CAGR [2] Financial Performance - UFP Technologies surpassed $500 million in sales for the first time in 2024, achieving 15.1% annualized revenue growth and 24.9% EPS growth over the past decade [3] - Q2 2025 revenue rose 37.2% year over year, indicating accelerated momentum in financial performance [3] Operational Strengths - The company maintains a 29.1% gross margin in 2024, above its five-year average, supported by low-cost country manufacturing and disciplined acquisition integration [4] - UFP Technologies has a strong balance sheet with debt at 32% of total capital, trending downward, which provides flexibility for strategic acquisitions and targets 15% annual EPS growth over the next five years [4] Investment Case - The stock is currently in an attractive Buy Zone, offering a projected 16.5% total annual return and a favorable 3.1-to-1 upside-to-downside ratio [5] - Resilient end markets, disciplined capital allocation, and accelerating growth support a strong long-term investment case for UFP Technologies [5]

Core Thesis - UFP Technologies, Inc. is positioned as a high-quality growth investment in the medical device manufacturing sector, focusing on engineered materials and custom development [2][3] Company Overview - UFP Technologies designs and manufactures solutions for medical devices, sterile packaging, and engineered custom products in the United States [2] - The company serves high-growth medical segments, including single-use devices, sterile packaging, and robotic surgery, which is expanding at a mid-teens CAGR [2] Financial Performance - UFP surpassed $500 million in sales for the first time in 2024, achieving 15.1% annualized revenue growth and 24.9% EPS growth over the past decade [3] - Q2 2025 revenue rose 37.2% year over year, indicating accelerated momentum [3] Operational Efficiency - The company achieved a 29.1% gross margin in 2024, above its five-year average, supported by low-cost country manufacturing and disciplined acquisition integration [4] - The balance sheet shows debt at 32% of total capital, trending downward, which provides flexibility for strategic acquisitions [4] Investment Potential - The stock is currently in an attractive Buy Zone, with a projected 16.5% total annual return and a favorable 3.1-to-1 upside-to-downside ratio [5] - Resilient end markets, disciplined capital allocation, and accelerating growth support a strong long-term investment case [5]

Financial Performance - Net sales for the year ended December 31, 2025 increased 19.5% to $602.8 million from $504.4 million in 2024, driven by a 23.2% growth in sales to medical market customers [137]. - The companies acquired in 2024 and 2025 contributed approximately $168.3 million in sales for the year ended December 31, 2025, compared to $73.1 million in the same period last year [143]. - Gross profit margin decreased to 28.3% for the year ended December 31, 2025, down from 29.1% in 2024, primarily due to increased overhead and labor costs [144]. - Selling, General, and Administrative Expenses (SG&A) rose 24.5% to $77.4 million for the year ended December 31, 2025, with SG&A as a percentage of sales increasing to 12.8% [145]. - Net interest expense increased to approximately $9.8 million for the year ended December 31, 2025, up from $8.1 million in 2024, due to higher average debt levels [149]. - The effective tax rate for the year ended December 31, 2025 was 17.2%, a decrease from 19.2% in 2024, due to a favorable mix of pre-tax income [151]. - The AJR Labor Issue added over $6.3 million in incremental labor costs to the cost of sales for the year ended December 31, 2025 [138]. Cash Flow and Investments - Net cash provided by operations for the year ended December 31, 2025 was approximately $91.9 million, resulting from net income of approximately $68.3 million [155]. - Net cash used in investing activities was approximately $27.6 million, primarily for manufacturing machinery, equipment, and acquisitions [156]. - The company generated approximately $91.9 million in cash from operations for the year ended December 31, 2025 [164]. Debt and Liquidity - Outstanding borrowings under the Third Amended and Restated Credit Agreement were approximately $135.5 million as of December 31, 2025, with a weighted average interest rate of approximately 5.1% [161]. - Future maturities of long-term debt total $135.455 million, with $109.375 million due in 2026-2028 and $26.080 million in 2029 [163]. - The company’s liquidity is contingent upon future operating performance and the availability of draws on its revolving credit facility [164]. Future Outlook and Risks - The company plans to enhance manufacturing capacity and may consider acquisitions to support anticipated growth [165]. - Future capital requirements for expansions and acquisitions could be substantial, relying on existing resources and cash flow from operations [166]. - Economic uncertainties, including inflation and bank failures, could impact the company's long-term capital access [164]. - Market risk includes fluctuations in interest rates, with a weighted average interest rate of approximately 5.1% as of December 31, 2025 [171]. - Interest on credit facilities ranges from SOFR plus 1.25%-2.25% or the bank's prime rate plus 0.25%-1.25% [171]. Accounting and Tax Considerations - The enactment of the "One Big Beautiful Bill Act" (OBBBA) includes key tax provisions, but its impact on income tax expense is considered immaterial [167]. - The company evaluates critical accounting estimates based on historical experience and current economic conditions, which may affect reported financials [168].

Group 1 - UFP Technologies, Inc. will participate in the Raymond James 47th Annual Institutional Investors Conference in Orlando, Florida from March 1-4, 2026, with a presentation scheduled for March 3 at 2:50 PM [1] - The company specializes in contract development and manufacturing of single-use and single-patient medical devices, serving as a crucial link in the medical device supply chain [2] - UFP Technologies is a valued outsourcing partner for leading medical device manufacturers, providing components for various applications including minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants [2]

Financial Data and Key Metrics Changes - Sales grew 19.5% for the full year, reaching total revenue of $602.8 million, marking a significant milestone and nearly tripling revenue since 2021 [4] - Operating income increased by 435% and EPS grew by 419% over the same four-year period [4] - 2025 EPS grew 15.4%, despite absorbing $6.3 million in labor inefficiencies at the Illinois AJR facility [4][5] - Gross profit margin decreased to 28.3% in 2025 due to additional labor costs, but would have increased to 29.3% without these costs [10] - Adjusted operating margin for the year was 17.1% of sales, within the target range of 17%-20% [10] - Cash from operations was approximately $92 million, with a leverage ratio of about 1.1 times at year-end [11] Business Line Data and Key Metrics Changes - Significant progress was made in expanding capabilities and capacity in the Dominican Republic, with new programs launched in Santiago and La Romana [5][6] - The AJR facility's labor inefficiency impact decreased from $3 million in Q3 to $1.2 million in Q4, indicating improved onboarding and training [5] - New business and capabilities were added in the orthopedic sterile packaging space in Ireland, enhancing global offerings [6] Market Data and Key Metrics Changes - Overall sales were positively impacted by growth in safe patient handling, infection control, and orthopedic packaging medical submarkets [9] - Organic sales growth for the year was low single digits, attributed to high sales in robotic surgery in 2024 and backlog issues in safe patient handling [9] Company Strategy and Development Direction - The company is focused on strategic initiatives such as contract extensions, program launches, and facility expansions [4][6] - A robust pipeline of new growth opportunities is in place, with ongoing efforts to identify strategic acquisitions [7] - The transition planning for the new CEO is nearly complete, with expectations for continued growth and strategic execution [7][55] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth, citing strong customer relationships and a solid foundation for the next several years [55] - The company is addressing labor challenges and expects continued progress in reducing backlog and improving operational efficiency [16][17] - The cybersecurity incident had minimal operational impact, with systems being restored and operations continuing effectively [8][9][26] Other Important Information - The company has cybersecurity insurance and does not expect a material impact on operations or liquidity from the recent breach [9] - The sixth building in the Dominican Republic is expected to be operational by April, further expanding robotic surgery capacity [6][31] Q&A Session Summary Question: Volume expectations with the largest customer for 2026 and 2027 - Management indicated that while the contract extension is beneficial, they cannot disclose specific volume increases due to customer confidentiality [14][15] Question: Impact of AJR labor inefficiencies on Q1 and 2026 - Management expects Q1 impact to be less than Q4, with ongoing improvements anticipated throughout the year [16][17] Question: Drivers of growth in med tech for 2026 - Management expects robust growth in patient services and has launched new programs in infection prevention and robotic surgery [22][23] Question: Cybersecurity incident and its impact on growth rates - Management confirmed that while there were delays in shipping, production continued, and they do not expect a material impact on Q1 [25][26] Question: Details on the sixth facility investment and timeline - Management stated that co-investment is typical with major contracts, and they will take possession of the sixth building in April [30][31] Question: Market size and growth potential in safe patient handling - Management indicated that the safe patient handling market is large and growing, with expectations for robust growth in the coming years [33] Question: Updates on AJR backlog and program transfers - Management noted that backlog is higher than previously disclosed and expects gradual reduction throughout 2026 [48]